Farhad Sheikhnia

Dr. Farhad Sheikhnia

Clinical Biochemistry, Urmia University of Medical Sciences, Urmia, Iran
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Biological Chemistry
Verified
Journal Article
Closed access
PDF file
MKMohsen Khosravi
Mohsen Khosravi
APAdeleh Poursaleh
Adeleh Poursaleh
GGGhasem Ghasempour
Ghasem Ghasempour
Farhad SheikhniaFarhad Sheikhnia
Farhad Sheikhnia
MNMohammad Najafi
Mohammad Najafi
Atherosclerosis is a cardiovascular disease (CVD) known widely world wide. Several hypothesizes are suggested to be involved in the narrowing of arteries during process of atherogenesis. The oxidative modification hypothesis is related to oxidative and anti-oxidative imbalance and is the most investigated. The aim of this study was to review the role of oxidative stress in atherosclerosis. Furthermore, it describes the roles of oxidative/anti-oxidative enzymes and compounds in the macromolecular and lipoprotein modifications and in triggering inflammatory events. The reactive oxygen (ROS) and reactive nitrogen species (RNS) are the most important endogenous sources produced by non-enzymatic and enzymatic [myeloperoxidase (MPO), nicotinamide adenine dinucleotide phosphate (NADH) oxidase and lipoxygenase (LO)] reactions that may be balanced with anti-oxidative compounds [glutathione (GSH), polyphenols and vitamins] and enzymes [glutathione peroxidase (Gpx), peroxiredoxins (Prdx), superoxide dismutase (SOD) and paraoxonase (PON)]. However, the oxidative and anti-oxidative imbalance causes the involvement of cellular proliferation and migration signaling pathways and macrophage polarization leads to the formation of atherogenic plaques. On the other hand, the immune occurrences and the changes in extra cellular matrix remodeling can develop atherosclerosis process.

20 April 2023 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
SHSepideh Hassani
Sepideh Hassani
HMHossein Maghsoudi
Hossein Maghsoudi
FFFahimeh Fattahi
Fahimeh Fattahi
FMFaezeh Malekinejad
Faezeh Malekinejad
NHNooshin Hajmalek
Nooshin Hajmalek
MGMansour Ghorbanpour
Mansour Ghorbanpour

12 December 2023 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
Farhad SheikhniaFarhad Sheikhnia
Farhad Sheikhnia
VRVahid Rashidi
Vahid Rashidi
HMHossein Maghsoudi
Hossein Maghsoudi
MMMaryam Majidinia
Maryam Majidinia
Colorectal neoplasms are one of the deadliest diseases among all cancers worldwide. Thymoquinone (TQ) is a natural compound of Nigella sativa that has been used in traditional medicine against a variety of acute/chronic diseases such as asthma, bronchitis, rheumatism, headache, back pain, anorexia, amenorrhea, paralysis, inflammation, mental disability, eczema, obesity, infections, depression, dysentery, hypertension, gastrointestinal, cardiovascular, hepatic, and renal disorders. This review aims to present a detailed report on the studies conducted on the anti-cancer properties of TQ against colorectal cancer, both in vitro and in vivo. TQ stands as a promising natural therapeutic agent that can enhance the efficacy of existing cancer treatments while minimizing the associated adverse effects. The combination of TQ with other anti-neoplastic agents promoted the efficacy of existing cancer treatments. Further research is needed to acquire a more comprehensive understanding of its exact molecular targets and pathways and maximize its clinical usefulness. These investigations may potentially aid in the development of novel techniques to combat drug resistance and surmount the obstacles presented by chemotherapy and radiotherapy. Graphical Abstract

29 May 2024 in Pathology - Research and Practice
Verified
Journal Article
Closed access
Farhad SheikhniaFarhad Sheikhnia
Farhad Sheikhnia
AFAhmad Fazilat
Ahmad Fazilat
VRVahid Rashidi
Vahid Rashidi
BABita Azizzadeh
Bita Azizzadeh
MMMahya Mohammadi
Mahya Mohammadi
MMMaryam Majidinia
Maryam Majidinia

16 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
HMHossein Maghsoudi
Hossein Maghsoudi
Farhad SheikhniaFarhad Sheikhnia
Farhad Sheikhnia
Przemyslaw SitarekPrzemyslaw Sitarek
Przemyslaw Sitarek
NHNooshin Hajmalek
Nooshin Hajmalek
SHSepideh Hassani
Sepideh Hassani
Tomasz KowalczykTomasz Kowalczyk
Tomasz Kowalczyk
Prostate cancer (PC) is the second most common type of cancer and the leading cause of death among men worldwide. Preventing the progression of cancer after treatments such as radical prostatectomy, radiation therapy, and hormone therapy is a major concern faced by prostate cancer patients. Inflammation, which can be caused by various factors such as infections, the microbiome, obesity and a high-fat diet, is considered to be the main cause of PC. Inflammatory cells are believed to play a crucial role in tumor progression. Therefore, nonsteroidal anti-inflammatory drugs along with their effects on the treatment of inflammation-related diseases, can prevent cancer and its progression by suppressing various inflammatory pathways. Recent evidence shows that nonsteroidal anti-inflammatory drugs are effective in the prevention and treatment of prostate cancer. In this review, we discuss the different pathways through which these drugs exert their potential preventive and therapeutic effects on prostate cancer.

1 January 2024 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
GGGhasem Ghasempour
Ghasem Ghasempour
FZFahimeh Zamani-Garmsiri
Fahimeh Zamani-Garmsiri
Farhad SheikhniaFarhad Sheikhnia
Farhad Sheikhnia
ASAli Akbar Soleimani
Ali Akbar Soleimani
SFSyed Reza Hosseini Fard
Syed Reza Hosseini Fard
MNMohammad Najafi
Mohammad Najafi
Background: Familial hypercholesterolemia (FH) is a prevalent and potentially fatal illness that causes a substantial elevation in low-density lipoprotein cholesterol (LDL-C). Methods: A comprehensive search was done on PubMed/MEDLINE, EMBASE, Web of Science (WOS/ ISI), Scopus, ClinicalTrials (www.ClinicalTrials.gov), and conferences/ congress research papers. Random effect models were used to calculate mean differences (%) and risk ratios (RRs), and confidence intervals (95%). Results: Ten studies (n=1489 patients) were included in this study. PCSK9 inhibitors decreased the levels of LDL-C by -49.59% (95%CI -55.5%, -43.67%) as compared to placebo. They also didn’t alter the Treatment-Emergent Adverse Event (TEAE) and neuronal events by RR 0.92 (0.75, 1.13) and 1.31 (0.66, 2.59), respectively. PCSK9 inhibitors were effective and safe in treating patients with FH. Conclusion: There was high-quality evidence showing that monoclonal antibodies (alirocumab & evolocumab) lower LDL-C (GRADE: high), lipoprotein (a) (GRADE: High), triglycerides (TG) (GRADE: High), total cholesterol (GRADE: High), non-high-density lipoprotein cholesterol (non- HDL-C) (GRADE: Moderate), and apolipoprotein B (GRADE: High), and increase the HDL-C (GRADE: High) as well as apolipoprotein A1 (GRADE: High). Comparing PCSK9 inhibitors against placebo, neither TEAE (GRADE: high) nor neuronal events (GRADE: moderate) were changed. Registration number: PROSPERO-CRD42022334035